Introduction
Diabetic nephropathy (DN) is the leading cause of chronic kidney disease and one of the most significant long-term complications in terms of morbidity and mortality for individual patients with diabetes. Major typical morphological changes are the progressive accumulation of extracellular matrix (ECM) proteins in mesangial interstitial space to lead to glomerular and tubular basement membrane thickening and increase of mesangial matrix, ultimately resulting in glomerulosclerosis and tubulointerstitial fibrosis. ECM is a potential protein source of diagnostic biomarkers for renal fibrosis [1, 2] , and among a large number of ECM proteins, Matrilin is a novel filamentous-forming adapter protein family, which can form collagen-dependent and -independent network of extracellular matrix [3] [4] [5] . Matrilin-2 is the largest member of the Matrilin family that shares von Willebrand factor A (vWFA) domains, epithelial growth factor (EGF) like repeats, and a series of heptad repeats at their C-terminal coiled-coil domain [6, 7] . Unlike other family members whose expression is limited to skeletal tissues, Matrilin-2 is found heterogeneously distributed in connective tissues, including kidney [8, 9] . It has previously been described that Matrilin-2 can interact with itself and a variety of matrix molecules including type 1 collagen, fibronectin, and laminin and has been postulated to act as an adaptor molecule connecting these molecules with other proteins and proteoglycans within the ECM where it may regulate ECM homeostasis [7, 10] . Therefore, Matrilin-2 may play an important role in DN pathogenesis.
Mesangial cells (MCs) located in the intercapillary space that are activated by numerous vasoactive substances as well as growth factors. Among various growth factors contributing to DN pathogenesis, transforming growth factor-β (TGF-β) is the key stimulator of ECM accumulation in the kidney [11] . It has been suggested that TGF-β significantly contributes to glomerular filtration barrier alteration, fibrosis and sclerosis, which reduce the filtration surface and finally cause glomerular collapse at the tubular level [12] . Studies with mouse models of diabetes showed antibodies against TGF-β prevented mesangial matrix accumulation [13] . TGF-β exerts its biological effects by binding to complexes of type I and II serine/threonine kinase receptor that further activates downstream mediators, Smad2 and Smad3 [14] .
Smad3 is critical for pro-fibrotic effect of TGF-β [15] [16] [17] and targeting Smad3 may have great therapeutic potential for kidney diseases. Interestingly, recent study showed that Matrilin-2 promoter harbored 7 putative Smad-binding sites [18, 19] . In this study, therefore, we investigated whether hyperglycemia was able to directly stimulate matrilin-2 overexpression and if this process was mediated by the TGF-β/Smad 3 pathway by using a mouse mesangial cell line.
Materials and Methods

Cell culture
Mouse mesangial cells (MMCs) (SV40 MES13) were obtained from the American Type Culture Collection (ATCC, Rockville, MD) and maintained in continuous culture at 37 o C/5% CO2 using DMEM/F-12 containing 5% FBS and 12 mM HEPES (pH 7.0).
MMCs grown in 100 mm culture dish with similar confluent were incubated with serum-free media for 48 hours to synchronize the cell growth. Then, cells were plated The 18S RNA was amplified at the same time and used as an internal control. The matrilin-2 mRNA level was normalized to housekeeping gene 18S RNA levels. Then the relative value of matrilin-2 mRNA was measured and calculated.
Protein extraction and Western Blotting Analysis
Western blotting was performed to determine Matrilin-2 protein expression level in (1:3000, 622101) (Biolegend, San Diego, CA) at 4°C overnight, then the bound horseradish peroxidase-conjugated secondary antibody was detected using an ECL detection system. Protein expression levels were determined by analyzing the signals captured on the nitrocellulose membranes using an image analyzer.
Statistics
Results were presented as the Mean±SD. Paired Student's t-tests were used for statistical analysis, p values less than 0.05 were considered significant.
Results
High glucose significantly induced Matrilin-2 expression.
To investigate whether Matrilin-2 was involved in DN, we observed the mRNA and protein expression levels of Matrilin-2 in SV40 MES 13 cells (MMCs) treated with the high concentration of glucose (30mM). Clearly, both Matrilin-2 mRNA and protein levels were significantly upregulated in a high glucose condition when comparing to normal glucose condition (p<0.05) (Figure 1, A, B, C) .
Inhibition of TGF-β1 and Smad3 suppressed high-glucose-induced Matrilin-2 expression.
We pre-treated MMCs with the specific TGF type I receptor kinase inhibitor SB-431542, followed by stimulation with 24h high glucose treatments. The western blot showed that SB-431542 markedly inhibited high glucose-induced Matrilin-2 expression at 10uM. Additionally, we applied Smad3 specific inhibitor SIS3 to cultured cells and demonstrated that SIS3 significantly inhibited high glucose-induced Matrilin-2 expression at a concentration of 10uM as well (Figure 2, A, B) .
TGF-β1 was able to stimulate expression of Matrilin-2 protein at time-dependent manner in MMCs
For further confirmation, we investigated whether TGF-β1 was able to directly induce Matrilin-2 expression in MMCs. Semi-quantitative analysis showed that after cultured MMCs were treated with 10ng/ml TGF-β1, Matrilin-2 expression was markedly induced in a time-dependent manner ( Figure 3.A, B) . The expression of Matrilin-2 was significantly elevated starting at 12h post TGF-β1 treatments (p<0.05) and reached to peak value at 24h (p<0.01).
TGF-β1/Smad3 inhibitors inhibited TGF-β1-induced Matrilin-2 expression in
MMCs.
As expected, both SB-431542 and SIS3 inhibited TGF-β1-induced Matrilin-2 expression (Figure 4 . A, B).
Discussion
In DN, changes in the ECM such as increased glomerular basement membrane thickness and the extracellular matrix of the mesangium expand occur in both type 1 and type 2 diabetes. The mesangial ECM is the main cause of declining renal function in DN provides structural support for the glomerular capillary convolute, connecting with the extraglomerular mesangium at the vascular pole and dysregulation of cell-matrix signaling plays an important role in DN [2] . It was found that hyperglycemia induced TGF-expression in experimental and human diabetes [20, 21] . Previous findings have demonstrated that high glucose stimulates TGF-β1 very early through its receptor [22, 23] . It was also demonstrated that TGF-bIIR played an important role in the progression of diabetic nephropathy through the intracellular Smad signaling [24] . Matrilin-2 was proved to be essential adaptor protein for the generation of muscle and nerve by TGF-β/Smad signaling pathway [25] , although it remained unknown whether Matrilin-2 was involved in DN pathogenesis and if the TGF-β1 played a role in regulating this protein. In this study, we clearly demonstrated that Matrilin-2 expression was induced by hyperglycemia and the TGF-β1/Smad3 pathway was involved in high glucose-induced Matrilin-2 expression in MMCs.
Here, the expression levels of Matrilin-2 mRNA and protein were significantly increased after MMCs had been treated with high glucose, suggesting that Matrilin-2 might be involved in the pathogenesis and progression of DN. Our previous study demonstrated that Matrilin-2 was mainly expressed in glomerulus, the basement membrane of distal convoluted tubule and renal matrix [8] , where was the typical lesion location in DN. Change of glucose metabolism could therefore activate intraand extracellular signaling pathways leading to abnormal ECM accumulation. This was the first time that Matrilin-2 was proved to be upregulated in MMCs under a high-glucose condition and our data suggested that Matrilin-2 accumulation might be an important damage factor for glomerular fibrosis in DN.
MMCs, locating in the intercapillary space, are vital for glomerulus to maintain normal physiological status. The response of MMCs under hyperglycemia condition is highly complex. Besides being exposed to extracellular glycated-proteins, MMCs activities are also affected and controlled by intracellular mediators, such as TGF-β1.
In renal diseases, TGF-β1 is upregulated and stimulates MMCs to produce ECM proteins, including type I, III and IV collagen, and laminin, contributing to glomerular ECM accumulation [12, 26] . In MMCs, it has been proved that TGF-β1/Smad3 signaling pathway could stimulates the synthesis and accumulation of ECM, and is associated with MMC hypertrophy in diabetes [12] . Here, we demonstrated that TGF-β1 and Smad3 mediated high glucose-induced Matrilin-2 activation in MMCs.
The biomarkers of tissue fibrosis have been investigated extensively in the pathogenesis of DN. Here our study revealed that Matrilin-2 could be induced by high glucose in MMCs through the TGF-β1/Smad3 signaling pathway. Our data may provide a potential diagnostic and therapeutic target for DN.
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